Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cetuximab plus docetaxel after docetaxel failure in advanced oesophago-gastric cancer
ACTRN12606000181505Phase 2Completed
- Sponsor
- Australasian Gastro-Intestinal Trials Group
- Start
- Feb 2006
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cetuximab and docetaxel in esophagogastric junction cancer, sponsored by Australasian Gastro-Intestinal Trials Group. Primary endpoint: Tumour response. Started Feb 2006; status: completed.
02
Drugs
cetuximabdocetaxel
03
Conditions
esophagogastric junction cancer
Beyond the preview
Go deeper on ACTRN12606000181505.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12606000181505.